1832 Asset Management
SRNE

1832 Asset Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

1832 Asset Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,200
Closed -$13K – 759
2020
Q3 		$13K Buy
+1,200
New +$11K ﹤0.01% 640

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

1832 Asset Management's SRNE Position: Q4 2020 in Review

1832 Asset Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2020, closing a stake of 1,200 shares — an estimated $13K sold.

1832 Asset Management first reported a position in SRNE in Q3 2020 and held it in 1 quarter. The position peaked at $13K in Q3 2020. 219 funds tracked by Wall St. Rank hold SRNE as of Q4 2020.

  • 1832 Asset Management reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • 1832 Asset Management sold 1,200 Sorrento Therapeutics, Inc. shares in Q4 2020, an estimated $13K.
  • 1832 Asset Management first reported a position in Sorrento Therapeutics, Inc. in Q3 2020 and held it in 1 quarter.
  • 1832 Asset Management's Sorrento Therapeutics, Inc. position peaked at $13K in Q3 2020.
  • 219 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2020.

Based on 1832 Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.